<div>
  <ul>
    <li>
      <p>
        Telepsychiatry platform Meru Health and clinical trial platform Curebase partnered to carry out a three-year clinical trial to measure the effectiveness of Meru Health&rsquo;s 12-week digital depression treatment targeting primary care patients.&nbsp;
      </p>
    </li>
    <li>
      <p>
        The clinical trial will be carried out in two phases; a proof-of-concept phase and a randomized controlled trial (RCT). The proof-of-concept phase will have two sample sets of 15 participants, one undergoing Meru Health&rsquo;s treatment and the other undergoing traditional treatments for depression, such as face-to-face therapy, antidepressants, or a combination of the two. The RCT will have a sample size of 300 participants and will collect electronic patient-reported outcomes for study upon completing Meru Health&rsquo;s treatment. The progress of the participants from the RCT will be monitored for up to a year to evaluate the long-term effects of Meru Health&rsquo;s treatment as well.&nbsp;
      </p>
    </li>
    <li>
      <p>
        The study was funded by the National Institutes of Health&rsquo;s Small Business Innovation Research program and is set to start recruitment in Autumn 2022 and close this process out by Spring 2023.&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.mobihealthnews.com/news/curebase-meru-health-partner-study-digital-depression-treatment">
      Mobi Health News
    </a>
  </p>
</div>


Clinical Trial Technology

Meru Health partners with Curebase to measure effectiveness of digital depression treatments

New technologies are opening up mental health services to previously overbooked and underserved populations.

All Updates

Meru Health partners with Curebase to measure effectiveness of digital depression treatments

Meru Health partners with Curebase to measure effectiveness of digital depression treatments

Curebase raised USD 40 million in Series B